Suzhou Fushilai Pharmaceutical Co., Ltd.
Pharmaceutical ingredients for medicine and dietary supplements
About Suzhou Fushilai Pharmaceutical Co., Ltd.
Suzhou Fushilai Pharmaceutical Co., Ltd. is a company that researches, develops, produces, and sells pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and raw materials for health products. Founded in November 2000, and formerly known as Changshu Fushilai Medicine & Chemical Co., Ltd., the company has grown significantly, expanding its facilities and moving to the Advanced Material Industrial Park in Changshu. The company went public on the Shenzhen Stock Exchange on March 29, 2022. Xiangyun Qian serves as the Chairman and General Manager.
The company's business model is centered on the manufacturing and global exportation of its core products, which include the lipoic acid series, carnosine series, and phosphatidylcholine series. These products are primarily supplied to the medicine, dietary supplement, and cosmetics industries. They are recognized for their benefits in anti-oxidation, delaying aging, and managing diabetic neuropathy. The company has established a global sales network, exporting to markets in Europe, America, and Southeast Asia, while also maintaining a significant market share in China. Fushilai operates under GMP (Good Manufacturing Practice) guidelines and has received certifications from the FDA.
Fushilai's main product lines feature a range of specialized ingredients. The lipoic acid series is used in medications for diabetic neuropathy complications. The L-carnosine series is applied in products aimed at delaying aging and in cosmetics. The phosphatidylcholine series is used in supplements for preventing conditions like neurasthenia and Alzheimer's disease. The company also produces other notable items such as imrecoxib API. In 2019, the company expanded its research and development capabilities by opening a new 8,000-square-meter R&D center.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2015
- Outcome tier
- Colt$25–100M revenue
News
Open roles
Suzhou Fushilai Pharmaceutical Co., Ltd. in its local ecosystem
The Suzhou Fushilai Pharmaceutical Co., Ltd. office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Suzhou International Development Venture Capital Holding
Source: Dealroom Talent Intelligence.
Global footprint
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Suzhou Fushilai Pharmaceutical Co., Ltd. on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Fushilai Pharmaceutical Co., Ltd. on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.